Humana, Inc. v. Mallinckrodt ARD LLC et al

Track this case

Case Number:

2:19-cv-06926

Court:

California Central

Nature of Suit:

Anti-Trust

Judge:

Dale S. Fischer

Firms

Companies

Sectors & Industries:

  1. May 27, 2021

    Judge Questions Bid To Move Acthar Cases To Delaware

    A member of the Judicial Panel on Multidistrict Litigation on Thursday questioned Mallinckrodt ARD LLC's push to have a battery of antitrust cases over sales of the anti-seizure drug Acthar transferred to federal court in Delaware where the company is currently making its way through bankruptcy proceedings.

  2. January 28, 2021

    Mallinckrodt Seeks To Move Acthar Cases To Delaware

    Mallinckrodt has urged federal courts around the country to transfer cases involving the drugmaker's hormone treatment Acthar that make claims for antitrust, racketeering and other violations to the Delaware court overseeing its bankruptcy.

  3. August 14, 2020

    Mallinckrodt Must Face Antitrust Claims Over Seizure Drug

    Mallinckrodt Ard LLC must face claims by Humana Inc. that it ran a scheme to keep a competitor to its infant spasm drug off the market after a California federal judge on Friday allowed the bulk of the claims in the suit to go forward.

  4. May 26, 2020

    Mallinckrodt Wants More Cuts To Seizure Drug Price Suit

    Mallinckrodt has asked a California federal judge to cut more antitrust claims from Humana's $700 million price-gouging lawsuit over an infant seizure syndrome treatment, claiming the insurer yet again defined the market too narrowly.

  5. March 11, 2020

    Humana Missed Mark On Market In Seizure Drug Suit

    A California federal judge has cut antitrust claims from Humana's suit accusing Mallinckrodt of orchestrating an "outrageous" price-gouging scheme for a hormone gel after finding problems with how the insurer defined the market, but left racketeering and state law claims intact.

  6. October 29, 2019

    Mallinckrodt Defends Price Hike As Necessary To Save Drug

    Mallinckrodt has urged a California federal judge to toss Humana's $700 million price-gouging lawsuit over an infant seizure syndrome treatment, arguing that the insurer cannot rely on settlements with federal antitrust enforcers to get around the fact that massive price increases were required to keep the therapy in production.

  7. August 09, 2019

    Humana Says Acthar's Meteoric Price Hike Cost It $700M

    Mallinckrodt ran "one of the most outrageous price-gouging schemes in the history of American medicine" on its hormone gel used primarily to treat an infant seizure syndrome, according to a new suit filed by Humana, which says the scheme has cost it more than $700 million.